Hemostatic and Inflammatory Biomarkers Associated with Suspected Restenosis after Percutaneous Coronary Intervention in Type 2 Diabetes
Downloads
Background: Diabetes-associated metabolic and inflammatory disturbances may contribute to recurrent coronary narrowing after percutaneous coronary intervention (PCI). Objective: To describe the distribution of hemostatic, metabolic, and inflammatory biomarkers in a previously reported clinical series stratified by suspected post-PCI restenosis. Methods: This descriptive manuscript is based on aggregate results reported from a 2022–2024 single-center cohort comprising 110 patients undergoing PCI and 30 apparently healthy comparators. Reported biomarkers included glycated hemoglobin (HbA1c), D-dimer, fibrinogen, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and HOMA-IR. Results: Suspected restenosis was reported in 42/110 patients (38.2%). Compared with the group without suspected restenosis, the suspected-restenosis group showed higher HbA1c (8.9 ± 1.1% versus 7.4 ± 0.8%), D-dimer (1.62 ± 0.41 versus 0.72 ± 0.19 μg/mL), and hs-CRP (6.9 ± 2.0 versus 3.8 ± 1.2 mg/L). Reported apparent ROC areas were 0.89 for D-dimer, 0.86 for fibrinogen, and 0.83 for hs-CRP; these estimates could not be independently verified. Conclusion: The reported biomarker patterns support further evaluation of integrated risk stratification, but diagnostic adjudication, patient-level analysis, and external validation are prerequisites to clinical deployment.
[1] N. Marx, M. Federici, K. Schütt, et al., “2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes,” European Heart Journal, vol. 44, no. 39, pp. 4043–4140, 2023, doi: 10.1093/eurheartj/ehad192. OUP Academic
[2] C. Vrints, F. Andreotti, K. C. Koskinas, et al., “2024 ESC Guidelines for the management of chronic coronary syndromes,” European Heart Journal, vol. 45, no. 36, pp. 3415–3537, 2024, doi: 10.1093/eurheartj/ehae177. OUP Academic
[3] J. A. Beckman, M. A. Creager, and P. Libby, “Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management,” JAMA, vol. 287, no. 19, pp. 2570–2581, 2002, doi: 10.1001/jama.287.19.2570. PubMed
[4] N. A. Rakhimov and S. A. Naimova, Method for Optimizing the Prevention of Restenosis After Coronary Intervention in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease. Bukhara, Uzbekistan, 2025. Institutional methodological recommendation.
[5] N. A. Rakhimov and S. A. Naimova, “Clinical significance of hemostasis biomarkers in preventing post-PCI restenosis in patients with type 2 diabetes mellitus and ischemic heart disease,” unpublished manuscript.
[6] R. Mehran, G. Dangas, A. S. Abizaid, et al., “Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome,” Circulation, vol. 100, no. 18, pp. 1872–1878, 1999, doi: 10.1161/01.cir.100.18.1872. PubMed
[7] G. W. Stone, A. Rizvi, W. Newman, et al., “Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease,” New England Journal of Medicine, vol. 362, no. 18, pp. 1663–1674, 2010, doi: 10.1056/NEJMoa0910496.
[8] G. W. Stone, J. F. Moses, S. G. Ellis, et al., “Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents,” New England Journal of Medicine, vol. 356, no. 10, pp. 998–1008, 2007, doi: 10.1056/NEJMoa067193.
[9] M. J. Kern and B. D. Seto, Eds., The Interventional Cardiac Catheterization Handbook, 3rd ed. Philadelphia, PA, USA: Elsevier, 2013.
[10] F. W. A. Verheugt and M. L. Simoons, “Antiplatelet therapy in coronary artery disease,” European Heart Journal, clinical reviews and guideline literature on antithrombotic management.
[11] G. N. Levine, E. R. Bates, J. C. Blankenship, et al., “2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention,” Journal of the American College of Cardiology, vol. 58, no. 24, pp. e44–e122, 2011, doi: 10.1016/j.jacc.2011.08.007.
[12] F. J. Neumann, M. Sousa-Uva, A. Ahlsson, et al., “2018 ESC/EACTS Guidelines on myocardial revascularization,” European Heart Journal, vol. 40, no. 2, pp. 87–165, 2019, doi: 10.1093/eurheartj/ehy394.
[13] J. S. Lawton, J. E. Tamis-Holland, S. Bangalore, et al., “2021 ACC/AHA/SCAI Guideline for coronary artery revascularization,” Journal of the American College of Cardiology, vol. 79, no. 2, pp. e21–e129, 2022, doi: 10.1016/j.jacc.2021.09.006.
[14] P. Libby, “The changing landscape of atherosclerosis,” Nature, vol. 592, pp. 524–533, 2021, doi: 10.1038/s41586-021-03392-8.
[15] P. R. Moreno and V. Fuster, “New aspects in the pathogenesis of diabetic atherothrombosis,” Journal of the American College of Cardiology, vol. 44, no. 12, pp. 2293–2300, 2004.

